GlaxoSmithKlineThe Impact of Medicines - Annual Review 2002
Reporting Front PageDownloads

Annual Review 2002 home
Chairman and Chief Executive Officer's statement
Patients and product development
R&D productivity
Innovative science
Diseases of the developing world
Our people
Corporate and social responsibility
Product portfolio
The Board
The Corporate Executive Team
Business operating review
Responsibility statement
Corporate governance
Summary financial statement
Summary financial statement in US dollars
Summary US GAAP information
Summary remuneration report
Shareholder information
Contact details
Summary Information under US GAAP for the year to 31st December 2002
 
Previous
Next

The following is a summary of the material adjustments to profit and shareholders’ funds which would be required if US Generally Accepted Accounting Principles (GAAP) had been applied instead of UK GAAP. These adjustments have been reflected in the income statements and balance sheet presented in accordance with US GAAP.

        2001  
    2002   (restated)  
  Profit £m   £m  
  Profit attributable to shareholders under UK GAAP 3,915   3,053  
  US GAAP adjustments:        
    Fixed assets 45   15  
    Intangible assets and goodwill (4,252 ) (3,667 )
    Inventory -   (298 )
    Disposal of investments, subsidiaries and products 7   87  
    Employee costs (469 ) (174 )
    Provision against ESOT shares 51   (108 )
    Derivative instruments 8   15  
    Restructuring 37   182  
    Taxation 1,169   827  
    Impairment of equity investments (8 ) (75 )
  Net income/(loss) under US GAAP before cumulative changes in accounting principles 503   (143 )
  Cumulative effect of changes in accounting principle (90 ) -  
  Net income/(loss) under US GAAP after cumulative effect of changes in accounting principles 413   (143 )
  Basic and diluted loss per share under US GAAP:        
    Net income/(loss) before cumulative changes in accounting principles 8.5 p (2.4 )p
    Changes in accounting principles (1.5) p -  
    Net income/(loss) after changes in accounting principles 7.0 p (2.4 )p


        2001  
    2002   (restated)  
   Equity shareholders' funds £m   £m  
  Equity shareholders' funds under UK GAAP 6,581   7,390  
  US GAAPadjustments:        
    Fixed assets 215   170  
    Investments 829   879  
    Intangible assets and goodwill 36,141   40,478  
    Unrealised gains on marketable securities 113   163  
    Employee costs (1,198 ) 299  
    Employee Share Ownership Trust (2,826 ) (2,936 )
    Restructuring costs (6 ) (46 )
    Derivative instruments 98   29  
    Dividends 754   718  
    Deferred taxation (5,729 ) (7,037 )
  Shareholders' equity under US GAAP 34,922   40,107  

Certain items for the year ended 31st December 2001 have been reclassified for comparative purposes.

A summary of the material differences between UK and US GAAP that apply to the Group is set out in the Annual Report 2002. Changes arising in 2002 are as follows:

During 2002 FRS 19 ‘Deferred tax’ has been implemented by the Group under UK GAAP. This FRS requires deferred tax to be accounted for on a full provision basis, rather than a partial provision basis as in 2001 and earlier years. This change has been accounted for as a prior period adjustment for UK GAAP purposes and comparative adjustments to arrive at US GAAP have been restated as necessary. This change has had no impact on US GAAP results.

The Group adopted SFAS 142, ‘Goodwill and other Intangible Assets’ as of 1st January 2002. The implementation of SFAS 142 resulted in no impairment of the Group’s goodwill and a revised initial impairment of £173 million, (£127 million net of tax) on indefinite lived assets. This is shown as a cumulative effect of an accounting change.

In addition, during 2002 the Group decided to align the measurement date for all of its pension plans. The impact, reflected as a cumulative effect of an accounting change, was a £37 million credit, net of tax, to income.

 
Previous
Next


Top


Annual Review 2002 Home | Reporting Front Page | Downloads | Main Site

 
Updated March 28, 2003 - © 2005 GlaxoSmithKline - All Rights Reserved
Legal Notices - Privacy Statement